EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS

C. H. Mortimer, D. Carr, T. Lind, S. R. Bloom, C. N. Mallinson, Andrew V Schally, W. M G Tunbridge, Lynne Yeomans, D. H. Coy, A. Kastin, G. M. Besser, R. Hall

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Growth-hormone release-inhibiting hormone (G.H.-R.I.H.) impairs the release of glucagon and insulin as well as G.H. during oral glucose tolerance and intravenous arginine tests; patients with acromegaly, diabetes mellitus, and hypopituitarism as well as healthy individuals were studied. Reciprocal changes in non-esterified fatty acids and plasma-insulin were seen. During the glucose-tolerance tests the rise in plasma-glucose was delayed and the peak values were often higher and more sustained after G.H.-R.I.H. than in control studies, so that glucose tolerance was impaired. Plasma-glucagon levels were suppressed by G.H.-R.I.H. in a patient with a glucagon-secreting tumour.

Original languageEnglish
Pages (from-to)697-701
Number of pages5
JournalThe Lancet
Volume303
Issue number7860
DOIs
StatePublished - Apr 20 1974
Externally publishedYes

Fingerprint

Glucagon
Growth Hormone
Hormones
Insulin
Glucose Tolerance Test
Hypopituitarism
Acromegaly
Glucose Intolerance
Arginine
Diabetes Mellitus
Fatty Acids
Glucose
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS. / Mortimer, C. H.; Carr, D.; Lind, T.; Bloom, S. R.; Mallinson, C. N.; Schally, Andrew V; Tunbridge, W. M G; Yeomans, Lynne; Coy, D. H.; Kastin, A.; Besser, G. M.; Hall, R.

In: The Lancet, Vol. 303, No. 7860, 20.04.1974, p. 697-701.

Research output: Contribution to journalArticle

Mortimer, CH, Carr, D, Lind, T, Bloom, SR, Mallinson, CN, Schally, AV, Tunbridge, WMG, Yeomans, L, Coy, DH, Kastin, A, Besser, GM & Hall, R 1974, 'EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS', The Lancet, vol. 303, no. 7860, pp. 697-701. https://doi.org/10.1016/S0140-6736(74)92903-1
Mortimer, C. H. ; Carr, D. ; Lind, T. ; Bloom, S. R. ; Mallinson, C. N. ; Schally, Andrew V ; Tunbridge, W. M G ; Yeomans, Lynne ; Coy, D. H. ; Kastin, A. ; Besser, G. M. ; Hall, R. / EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS. In: The Lancet. 1974 ; Vol. 303, No. 7860. pp. 697-701.
@article{d74c2850e3114a6baf00beea3931a2dd,
title = "EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS",
abstract = "Growth-hormone release-inhibiting hormone (G.H.-R.I.H.) impairs the release of glucagon and insulin as well as G.H. during oral glucose tolerance and intravenous arginine tests; patients with acromegaly, diabetes mellitus, and hypopituitarism as well as healthy individuals were studied. Reciprocal changes in non-esterified fatty acids and plasma-insulin were seen. During the glucose-tolerance tests the rise in plasma-glucose was delayed and the peak values were often higher and more sustained after G.H.-R.I.H. than in control studies, so that glucose tolerance was impaired. Plasma-glucagon levels were suppressed by G.H.-R.I.H. in a patient with a glucagon-secreting tumour.",
author = "Mortimer, {C. H.} and D. Carr and T. Lind and Bloom, {S. R.} and Mallinson, {C. N.} and Schally, {Andrew V} and Tunbridge, {W. M G} and Lynne Yeomans and Coy, {D. H.} and A. Kastin and Besser, {G. M.} and R. Hall",
year = "1974",
month = "4",
day = "20",
doi = "10.1016/S0140-6736(74)92903-1",
language = "English",
volume = "303",
pages = "697--701",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7860",

}

TY - JOUR

T1 - EFFECTS OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE ON CIRCULATING GLUCAGON, INSULIN, AND GROWTH HORMONE IN NORMAL, DIABETIC, ACROMEGALIC, AND HYPOPITUITARY PATIENTS

AU - Mortimer, C. H.

AU - Carr, D.

AU - Lind, T.

AU - Bloom, S. R.

AU - Mallinson, C. N.

AU - Schally, Andrew V

AU - Tunbridge, W. M G

AU - Yeomans, Lynne

AU - Coy, D. H.

AU - Kastin, A.

AU - Besser, G. M.

AU - Hall, R.

PY - 1974/4/20

Y1 - 1974/4/20

N2 - Growth-hormone release-inhibiting hormone (G.H.-R.I.H.) impairs the release of glucagon and insulin as well as G.H. during oral glucose tolerance and intravenous arginine tests; patients with acromegaly, diabetes mellitus, and hypopituitarism as well as healthy individuals were studied. Reciprocal changes in non-esterified fatty acids and plasma-insulin were seen. During the glucose-tolerance tests the rise in plasma-glucose was delayed and the peak values were often higher and more sustained after G.H.-R.I.H. than in control studies, so that glucose tolerance was impaired. Plasma-glucagon levels were suppressed by G.H.-R.I.H. in a patient with a glucagon-secreting tumour.

AB - Growth-hormone release-inhibiting hormone (G.H.-R.I.H.) impairs the release of glucagon and insulin as well as G.H. during oral glucose tolerance and intravenous arginine tests; patients with acromegaly, diabetes mellitus, and hypopituitarism as well as healthy individuals were studied. Reciprocal changes in non-esterified fatty acids and plasma-insulin were seen. During the glucose-tolerance tests the rise in plasma-glucose was delayed and the peak values were often higher and more sustained after G.H.-R.I.H. than in control studies, so that glucose tolerance was impaired. Plasma-glucagon levels were suppressed by G.H.-R.I.H. in a patient with a glucagon-secreting tumour.

UR - http://www.scopus.com/inward/record.url?scp=0015952818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015952818&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(74)92903-1

DO - 10.1016/S0140-6736(74)92903-1

M3 - Article

VL - 303

SP - 697

EP - 701

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7860

ER -